JP2000500019A5 - - Google Patents

Download PDF

Info

Publication number
JP2000500019A5
JP2000500019A5 JP1997518551A JP51855197A JP2000500019A5 JP 2000500019 A5 JP2000500019 A5 JP 2000500019A5 JP 1997518551 A JP1997518551 A JP 1997518551A JP 51855197 A JP51855197 A JP 51855197A JP 2000500019 A5 JP2000500019 A5 JP 2000500019A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997518551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000500019A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1996/004850 external-priority patent/WO1997018314A1/de
Publication of JP2000500019A publication Critical patent/JP2000500019A/ja
Publication of JP2000500019A5 publication Critical patent/JP2000500019A5/ja
Ceased legal-status Critical Current

Links

JP9518551A 1995-11-16 1996-11-06 ストレプトアビジン融合タンパク質経由でのペプチドの生産方法 Ceased JP2000500019A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19542702 1995-11-16
DE19542702.5 1995-11-16
PCT/EP1996/004850 WO1997018314A1 (de) 1995-11-16 1996-11-06 Verfahren zur herstellung von peptiden über streptavidin-fusionsproteine

Publications (2)

Publication Number Publication Date
JP2000500019A JP2000500019A (ja) 2000-01-11
JP2000500019A5 true JP2000500019A5 (https=) 2004-11-04

Family

ID=7777604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9518551A Ceased JP2000500019A (ja) 1995-11-16 1996-11-06 ストレプトアビジン融合タンパク質経由でのペプチドの生産方法

Country Status (6)

Country Link
US (1) US6136564A (https=)
EP (1) EP0861325A1 (https=)
JP (1) JP2000500019A (https=)
AU (1) AU7566396A (https=)
CA (1) CA2237296C (https=)
WO (1) WO1997018314A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168718A1 (en) * 1997-04-03 2002-11-14 California Institute Of Technology Enzyme-mediated modification of fibrin for tissue engineering
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
ES2368988T3 (es) 1999-02-01 2011-11-24 Eidgenössische Technische Hochschule Zürich Bio-materiales formados por reacción de adición nucleófila a grupos insaturados conjugados.
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
WO2000075333A1 (en) * 1999-06-07 2000-12-14 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7291673B2 (en) * 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
MXPA04006021A (es) * 2001-12-18 2005-08-19 Eth Zuerich Matrices de proteina modificada con factor de crecimiento para ingenieria de tejidos.
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
EP1465989B1 (en) * 2001-12-18 2008-02-20 Eidgenossisch Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US8282912B2 (en) * 2002-03-22 2012-10-09 Kuros Biosurgery, AG Compositions for tissue augmentation
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
AU2005318097A1 (en) * 2004-12-22 2006-06-29 Kuros Biosurgery Ag Michael-type addition reaction functionalised peg hydrogels with factor XIIIA incorporated biofactors
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
SG161218A1 (en) * 2005-01-06 2010-05-27 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
PL2136850T3 (pl) * 2007-04-13 2012-07-31 Kuros Biosurgery Ag Polimeryczny uszczelniacz tkankowy
CA2710798A1 (en) * 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
KR20120108967A (ko) * 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
EP2686027B1 (en) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmaceutical formulation for use in spinal fusion
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002077A1 (en) * 1984-10-02 1986-04-10 Meade Harry M Production of streptavidin-like polypeptides
GB8518753D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Microbiological products
DE3878231T2 (de) * 1987-03-02 1993-05-27 Bissendorf Peptide Gmbh Neues cadiodilatin-fragment, prozess zu dessen herstellung und dessen anwendung.
GB8723661D0 (en) * 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
ATE253639T1 (de) * 1991-08-19 2003-11-15 Daiichi Suntory Pharma Co Ltd Verfahren zur herstellung von peptiden

Similar Documents

Publication Publication Date Title
JP2000500445A5 (https=)
JP2000500033A5 (https=)
JP2000500440A5 (https=)
JP2000500327A5 (https=)
JP2000500145A5 (https=)
JP2000500155A5 (https=)
JPH11507533A5 (https=)
JP2000500115A5 (https=)
JP2000500322A5 (https=)
JP2000500192A5 (https=)
JP2000500112A5 (https=)
JP2000500226A5 (https=)
JPH11506886A5 (https=)
JP2000500051A5 (https=)
JP2000500407A5 (https=)
JP2000500166A5 (https=)
JP2000500019A5 (https=)
JP2000500125A5 (https=)
JP2000500044A5 (https=)
JPH10510459A5 (https=)
JP2000500090A5 (https=)
JP2000500429A5 (https=)
JP2000500106A5 (https=)
JPH11513276A5 (https=)
JP2000500265A5 (https=)